KROS Stock Summary and Trading Ideas (Keros Therapeutics | NASDAQ:KROS)

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Keros Therapeutics trades on the NASDAQ stock market under the symbol KROS.

As of July 30, 2026, KROS stock price climbed to $10.22 with 129,553 million shares trading.

KROS has a beta of 1.37, meaning it tends to be more sensitive to market movements. KROS has a correlation of 0.10 to the broad based SPY ETF.

KROS has a market cap of $202.23 million. This is considered a Small Cap stock.

Last quarter Keros Therapeutics reported $367,000 in Revenue and -$1.21 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.29.

In the last 3 years, KROS traded as high as $73.00 and as low as $9.12.

The top ETF exchange traded funds that KROS belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

KROS has underperformed the market in the last year with a price return of -29.4% while the SPY ETF gained +17.9%. KROS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -7.9% and -7.3%, respectively, while the SPY returned +4.5% and -1.7%, respectively.

KROS support price is $9.60 and resistance is $10.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KROS shares will trade within this expected range on the day.